Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR1B | P47901 | 18/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3131914 | 0.88 | AVPR1B (0.60) | AVPR1B | |
| SCHEMBL3127645 | 0.87 | AVPR1B (0.57) | AVPR1BALDH1A1 | |
| SCHEMBL3121722 | 0.87 | AVPR1B (0.56) | AVPR1B | |
| SCHEMBL3136602 | 0.86 | AVPR1B (0.73) | AVPR1B | |
| SCHEMBL3137962 | 0.86 | AVPR1B (0.69) | AVPR1B | |
| SCHEMBL3136852 | 0.85 | AVPR1B (0.57) | AVPR1B | |
| SCHEMBL3134143 | 0.82 | AVPR1B (0.85) | AVPR1B | |
| SCHEMBL3122791 | 0.79 | AVPR1B (0.65) | AVPR1B | |
| SCHEMBL3125557 | 0.78 | AVPR1B (0.62) | AVPR1B | |
| SCHEMBL3132840 | 0.77 | AVPR1B (0.66) | AVPR1BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807686-B2 | 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists | N.V. ORGANON (NL) | 2010-10-05 | — | — | US | disclosed |
| EP-1861380-B1 | 2-(4-OXO-4H-QUINAZOLIN-3-YL)ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | ORGANON NV (NL) | 2010-07-07 | — | — | EP | disclosed |
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | MERCK SHARP & DOHME B.V. (NL) | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | AVPR2, AVPR1A, AVPR1B | AVPR1B 3/4885LMNA 2726/4885TP53 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.